Because of increasing evidence of metabolic disturbances in amyotrophic lateral sclerosis patients, researchers at the University of Queensland tested whether ALS could be targeted at the metabolic level. Results indicate that by increasing energy sources with the triglyceride supplement triheptanoin, they could delay motor neuron loss in an animal model.
News
Engineers at MIT have developed a device that replicates the neuromuscular junction — the connection between motor neurons (the type of neurons that communicate and stimulate muscles, coming from the spinal cord) and muscle cells. The tool, which gives researchers access to technology in the lab that recreates how neurons stimulate muscles,…
Flex Pharma has begun a Phase 2 clinical trial assessing FLX-787 in patients with amyotrophic lateral sclerosis (ALS). The aim of the study, taking place in Australia, is to evaluate the safety and efficacy of FLX-787 in treating ALS-related leg cramps and/or spasticity. Patients with ALS — a…
Caregivers play an important role in the treatment and support of people with amyotrophic lateral sclerosis (ALS), although that role is not always appreciated or regarded by researchers. A recent study focused on the impact of caregiving on those who take care of people with ALS, highlighting how the disease affects both patients and those…
Although cognitive impairment is common in patients with ALS, the reliability of the “Reading the Mind in the Eyes Test” (RMET), a measure of social cognitive function, had yet to been established. Here, researchers confirm this is a reliable and efficient measure of social cognition in amyotrophic lateral sclerosis (ALS) patients,…
Magnetic resonance imaging (MRI) techniques may detect biomarkers for early diagnosis in patients with amyotrophic lateral sclerosis (ALS), according to a review study titled “The value of magnetic resonance imaging as a biomarker for amyotrophic lateral sclerosis: a systematic review,” published in BMC Neurology. Biomarkers are measurable substances, such…
Patients with amyotrophic lateral sclerosis (ALS) may have problems recognizing emotions in other people, even though they do not have other cognitive or behavioral problems. This inability is linked to microscopic changes in brain anatomy in regions linked to emotional processing, and resembles changes seen in patients with some types of…
A new study led by researchers with the United Nations (UN) has projected that the number of cases of amyotrophic lateral sclerosis (ALS) will increase by 69% over the next 25 years, primarily due to population ageing. According to the study “Projected increase in amyotrophic lateral sclerosis…
Astroglial cells in the brain were seen to contribute to the death of neurons by promoting inflammation in an in vitro laboratory model of sporadic amyotrophic lateral sclerosis (ALS). Astrocytes are brain cells that are usually known for their protective role toward neurons in conditions such as stroke and spinal cord injury. But…
The U.S. U.S. Food and Drug Administration (FDA) has accepted Mitsubishi Tanabe Pharma’s new drug application (NDA) for edaravone as a treatment for amyotrophic lateral sclerosis (ALS). A decision regarding the intravenous treatment is expected by June 16, 2017, based on the U.S. Prescription Drug User Fee Act. If it is…
Recent Posts
- Ahead of this year’s MDA Conference, association’s CEO speaks of ‘hope’
- Higher blood lactate levels tied to survival, weight changes in ALS
- AB Science adds new biomarker to Phase 3 masitinib ALS clinical trial
- ‘Early birds’ have significantly lower ALS risk than ‘night owls’: Study
- As my late husband’s ALS progressed, we kept our bucket list simple